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INTRODUCTION
Advanced-stage indolent non-Hodgkin’s lymphoma
(NHL) is typically characterized by high response rates but
inevitable relapse [1,2]. High-dose chemotherapy and autol-
ogous stem cell transplantation have been used cautiously in
this patient population because of the possible toxicities of
the procedure, the potential for long-term survival of
patients undergoing standard therapy, and the unknown
long-term outcomes of transplantation in these patients [3-5].
A potential concern with autografts in these patients is that a
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ABSTRACT
Purpose: To evaluate the results of high-dose chemotherapy and transplantation of highly purified “mobilized”
peripheral blood CD34+Thy-1+ hematopoietic stem cells (HSCs) in patients with recurrent indolent non-Hodgkin’s
lymphoma (NHL) or mantle cell lymphoma (MCL).
Patients and Methods: Twenty-six patients with recurrent indolent NHL or MCL were mobilized with either granulo-
cyte colony-stimulating factor (G-CSF) alone or cyclophosphamide plus G-CSF. Apheresis was performed, and the
product was purified using the Isolex immunomagnetic positive CD34+ cell selection device initially and subsequent
high-speed flow-cytometric cell sorting for the final purification of CD34+Thy-1+ HSCs. The patients received high-
dose chemotherapy with BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) followed by transplanta-
tion with the purified HSCs in 2 dose cohorts (cohort 1: ≥5 × 105 viable and pure HSC/kg; cohort 2: ≥3 × 105 HSC/kg).
Results: We attempted to mobilize 26 patients with G-CSF alone. Six patients did not collect adequate cells with
G-CSF alone; subsequent mobilization with cyclophosphamide plus G-CSF was attempted, but adequate
CD34+Thy-1+ HSCs could not be collected on these 6 patients. Twenty patients underwent transplantation with the
BEAC transplantation regimen followed by purified HSCs. Patients in cohort 1 engrafted at a median of day 12 to
an absolute neutrophil count (ANC) >500/µL, a median of day 19 for platelet transfusion independence, and a
median of day 20 for red blood cell transfusion independence. Patients in cohort 2 engrafted at a median of day 12
to an ANC >500/µL, a median of day 12 for platelet transfusion independence, and a median of day 12 for red blood
cell transfusion independence. Fourteen of the 20 patients had significant infections reported at some point post-
transplantation, including influenza, respiratory syncytial virus, pneumonitis, and Pneumocystis carinii pneumonia.
With a median follow-up of 38 months, 8 of the 20 patients have had progressive lymphoma and 5 patients have
died. The 3-year event-free survival is 55%, and overall survival is 78%.
Conclusions: CD34+Thy-1+ HSCs can be collected successfully from most lymphoma patients mobilized with
G-CSF alone. The engraftment and disease outcomes in the patients in this small pilot study using these cells do
not appear to be different from the outcomes of similar patients cited in the literature. However, the short- and
long-term risks of infection were a concern in this patient population.
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high percentage have bone marrow and peripheral blood
lymphomatous involvement [6]. In addition, the use of high-
dose chemotherapy and transplantation has not produced
long-term disease-free survival in patients with mantle cell
lymphoma (MCL) who are in relapse [7].
In most studies, the use of mobilized peripheral blood
progenitors in autologous transplantation has resulted in
rapid, stable long-term engraftment [8,9]. The rapidity of
the engraftment has been correlated with the CD34+ cell
content of the graft [10,11]. Within the CD34+ cell popula-
tion, considerable heterogeneity exists with respect to other
markers [12].
The subpopulation of CD34+ cells necessary for long-
term engraftment in humans is unknown. However, various
CD34+ cell selection devices have been evaluated in an
effort to positively select for the hematopoietic cells needed
for engraftment while eliminating tumor cells, which are
CD34– [13,14]. The initial selection devices selected only
for CD34+ cells, with no other fractionation. However,
investigators subsequently identified a subpopulation of
human cells with the cell surface phenotype of CD34+Thy-
1+Lin– that are found in both bone marrow and peripheral
blood after mobilization [12,15,16]. Highly selected
CD34+Thy-1+Lin– stem cells have demonstrated multilin-
eage potential according to in vitro and in vivo assays in
SCID mice and in utero sheep models [17,18].
This trial was a phase 1 study of highly purified
CD34+Thy-1+ stem cells given back following high-dose
chemotherapy in patients with recurrent NHL. The goals of
this study were to determine the feasibility of isolating sufﬁ-
cient numbers of extensively puriﬁed CD34+Thy-1+ cells by
high-speed fluorescence-activated cell sorting, to evaluate
the degree of tumor cell depletion, to determine the
engraftment of these highly selected cells, and to determine
the immune reconstitution and short- and long-term com-
plications in these transplantation patients.
PATIENTS AND METHODS
Patients
Patients at the University of Nebraska Medical Center
were enrolled in this study between November 1996 and
December 1997. Patients with NHL with the following his-
tologies were eligible for enrollment in this trial: small
lymphocytic lymphoma, follicular small cleaved lymphoma,
follicular mixed small and large cell lymphoma, follicular
large cell lymphoma, composite lymphoma with diffuse and
follicular lymphoma (<50% large cells), MCL, and monocy-
toid B-cell lymphoma (marginal zone lymphoma). Patients
were in ﬁrst partial remission, second complete remission,
or second partial remission following conventional induc-
tion and salvage chemotherapy. The patients had to have a
demonstrated chemotherapy-sensitive response with ≥50%
reduction of the bidimensional tumor mass. Additionally,
patients with MCL could have been in ﬁrst complete remis-
sion for this protocol. The patients had to have a Karnofsky
performance status ≥70%, with adequate cardiac, pul-
monary, renal, and hepatic function and without evidence of
active infection. The patients were adults with adequate
hematologic function premobilization as defined by an
absolute neutrophil count (ANC) ≥1.5 × 109/L and a platelet
count ≥120 × 109/L. Results of serologic tests for hepatitis B
and C and human immunodeficiency virus (HIV) were
required to be negative. All patients signed informed con-
sent forms approved by the Scientific Review Committee
and the Institutional Review Board of the University of
Nebraska Medical Center (Omaha, NE).
Screening Studies
Before mobilization, eligible patients were required to
have a complete history and physical examination, complete
blood count with differential and platelet count, radiologic
assessment of the lymphoma, bone marrow biopsy and aspi-
rate, pulmonary function assessments, ejection fraction eval-
uation, pregnancy test, coagulation profile, hepatitis and
HIV testing, chemistry profile, and urinalysis. Patients’
lymph node biopsies were also reviewed for conﬁrmation of
the diagnosis and for molecular analysis for bcl-1 (MCL) or
bcl-2 or for complementarity-determining region 3 (CDR
3) analysis in the case of other histologic types. 
Trial Design
This trial was an open-label, 2-cohort study with cell dose
de-escalation, evaluating autologous transplantation of varying
numbers of CD34+Thy-1+ HSCs. This dose de-escalation
design was chosen in an effort to identify the minimum num-
ber of selected cells necessary for adequate and sustained
engraftment that would allow for fewer aphereses. After con-
ﬁrmation of eligibility, the patients were mobilized with gran-
ulocyte colony-stimulating factor (G-CSF) alone. After 4 days
of G-CSF, the patients had hematopoietic progenitors har-
vested by leukapheresis. The ﬁrst cohort had a target of ≥5 ×
105 HSC/kg, and the second had a target of ≥3 × 105 HSC/kg
(Figure 1). The patients received the BEAC protocol (carmus-
tine 300 mg/m2 on day –7, etoposide 100 mg/m2 intravenously
[IV] twice daily on days –6 to –3, cytarabine 100 mg/m2 IV
twice daily on days –6 to –3, and cyclophosphamide 35 mg/kg
IV once daily on days –6 to –3). The puriﬁed HSCs were
administered on day 0 of the protocol.
Figure 1. Trial design, by cohort assignment.
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Mobilization
The patients were mobilized with G-CSF (Neupogen;
Amgen, Thousand Oaks, CA) alone at 24 (g/kg per day sub-
cutaneously. The dosage of 24 µg/kg per day of G-CSF was
chosen because it was believed a higher dose might optimize
the collections. On the day of the fourth injection of G-CSF,
daily apheresis was begun with 12- to 20-L exchanges on
the COBE Spectra apheresis machine (Gambro BCT, Den-
ver, CO). The product was shipped to SyStemix (Palo Alto,
CA) for cell processing. After successful collection of the
puriﬁed HSC product, collection of unmodiﬁed peripheral
blood progenitors from the patients continued, to obtain a
backup preparation with ≥1.5 × 106 CD34+ cells/kg. If ade-
quate puriﬁed HSCs could not be collected, an attempt at
chemotherapy mobilization was made. The 6 patients from
whom adequate purified HSCs could not be collected
received cyclophosphamide, 4 g/m2 IV, followed by G-CSF
at 10 µg/kg subcutaneously. When the white blood cell
count started to recover from the nadir, an attempt at
re-collection was made. We were still unable to collect a
puriﬁed HSC product from these 6 patients by this method.
However, these patients were all able to undergo transplan-
tation using the unmodiﬁed HSCs.
Stem Cell Isolation and Cryopreservation 
Mononuclear cells collected by apheresis were diluted to
a final concentration of <5 × 107 cells/mL in transport
medium before shipment to SyStemix. At SyStemix, each
patient sample was analyzed for cell number, viability, and
phenotype and was either processed immediately or held
overnight at room temperature. CD34+Thy-1+ HSCs were
initially purified using the Isolex (Baxter, Irvine, CA)
immunomagnetic positive selection device to enrich for
CD34+ cells, with subsequent high-speed flow-cytometric
cell sorting for the ﬁnal puriﬁcation of CD34+Thy-1+ HSCs.
The immunomagnetic CD34 selection process consisted
of the following: (1) labeling cells with an anti-CD34 mono-
clonal antibody (MoAb); (2) mixing cells with paramagnetic
beads coated with sheep antimouse immunoglobulin G
(IgG), with CD34+ cells forming rosettes with the beads; (3)
attaching the rosettes to a magnet and washing CD34– cells
from the system; and (4) releasing the cells from the beads
using a peptide mimotope that competes with the MoAb
binding site of the CD34 molecule. Residual erythrocytes, if
any, were lysed with 150 mmol/L ammonium chloride lysis
buffer, pH 7.5, for 5 minutes at 4°C. Before staining, the
cells were incubated with 0.1% human immunoglobulin
(Gammimune; Bayer, Berkeley, CA) for 10 minutes at 4°C
to block nonspecific binding. The cells were stained at a
concentration of 2 × 107 cells/mL for 20 minutes at 4°C
with SyStemix-manufactured MoAbs that recognize CD34
and Thy-1 antigens (2.5 µg/mL CD34 sulforhodamine,
2.5 µg/mL Thy-1 biotin). SyStemix’s fluoresceinated anti-
CD34 MoAb differed from the antibody used in the
immunomagnetic selection device. Without washing, strep-
tavidin (Societa Prodotti Antibiotici, Milan, Italy) was added
to the cells at a ﬁnal concentration of 0.15 mg/mL and incu-
bated for an additional 20 minutes. Cells were washed twice
in cold phosphate-buffered saline (PBS) with 1% human
serum albumin (HSA) (Alpha Therapeutics, Los Angeles,
CA), resuspended to 2 × 107 cells/mL in 5 µg/mL phycoery-
thrin (PE)-biotin (SyStemix) and incubated for 20 minutes
at 4°C. In preparation for sorting, the cells were washed
once with cold PBS/1% HSA, resuspended to 2 × 107
cells/mL in PBS/1% HSA plus 100 U/mL deoxyribonucle-
ase (DNAse) (Benzonase; Nycomed, Copenhagen, Den-
mark), and kept at a temperature of 2°C to 8°C.
The HSCs were sorted as previously described using
SyStemix’s proprietary dual-laser, fluorescence-activated,
high-speed clinical cell sorter [19]. PE was excited by an
argon laser emitting 488 nm light, and SRG was excited by a
rhodamine 6-G dye laser emitting 590 nm light. Forward-
and side-scatter sort windows were set to exclude very small
or very large cells and cell clusters. Selection criteria for
CD34 cells were based on the ﬂuorescence of unstained cells
(autoﬂuorescence), and the selection criteria for Thy-1 (PE)
were based on the background ﬂuorescence of cells stained
with anti–Thy-1 biotin and biotin-PE but lacking strepta-
vidin. Cells were sorted at a rate of 15,000 to 20,000 events
per second. The CD34+Thy-1+ cells were sorted directly into
a culture tube containing a small volume of SyStemix’s pro-
prietary culture medium and were stored at a temperature of
2°C to 8°C until cryopreservation.
The purified HSCs were washed free of sorter sheath
ﬂuid, counted with a hemocytometer, and resuspended to a
maximum of 4 × 107 cells/mL in SyStemix-manufactured
proprietary cryopreservation medium containing 2% het-
astarch, 4% HSA, and 7.5% dimethyl sulfoxide (DMSO) as
cryoprotectants. The cells were divided into aliquots and
placed into 2 or more cryovials. The cells were frozen using
a programmable step-down freezer with a freezing profile
optimized for HSC survival. The step-down freezer was
programmed to freeze at –1°C/min until the sample reached
a temperature of –45°C and then to freeze at –10°C/min
until the sample reached a temperature of –140°C. After the
product temperature reached –140°C, the vials were trans-
ferred to the liquid phase of a liquid nitrogen cryostorage
tank. Once the target dose was achieved and all products
were released, the HSC infusion products were shipped to
the clinical site in a liquid nitrogen shipper (CP65; Taylor-
Wharton Scientific, Harrisburg, PA) and returned to the
liquid phase of liquid nitrogen until the time of infusion.
Patients also had an unmodiﬁed backup collection per-
formed with >1.5 × 106 CD34+ cells/kg collected and cryop-
reserved by standard methods at the University of Nebraska
Medical Center.
Minimal Residual Disease Studies
Patients with indolent lymphomas had their initial lym-
phoma tissue block analyzed for the presence of bcl-2 or IgH
gene rearrangements by polymerase chain reaction (PCR)
analysis. In addition, the patients with MCL had their tissue
block analyzed for bcl-1 rearrangements. If patients were
found to have one of these abnormalities in their original tis-
sue, their stem cell products before and after processing were
examined by TaqMan Real-Time PCR. In this assay, the
TaqDNA polymerase cleaves a doubly labeled fluorogenic
probe. These nonextendable probes (TaqMan DNA probes;
Roche Molecular Systems, Pleasanton, CA), designed to
hybridize internally to the PCR primers, are labeled at the
5′ end with a reporter dye (ie, FAM, 6-carboxyﬂuorescein;
emission 518 nm). In addition, the 3′ end of the probe, which
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is labeled with TAMRA (6-carboxytetramethyl-rhodamine),
is phosphorylated to prevent extension of the probe during
the PCR. Fluorescence of the intact probe is quenched
mainly by Forster-type energy transfer while the nuclease
degradation of the probe results in an increase in reporter
dye ﬂuorescence. This is proportional to the concentration
of template in the PCR [20]. This real time–based assay has a
detection limit of 1/50,000 cells or 0.002%, with quantita-
tion by 10/50,000 cells [21].
High-Dose Therapy and Stem Cell Infusion
After the appropriate HSC and unmodified backup
hematopoietic stem cell collections were obtained, the
patients received the BEAC regimen (carmustine 300 mg/m2
on day –7, etoposide 100 mg/m2 twice daily on days –6 to –3,
cytarabine 100 mg/m2 twice daily on days –6 to –3,
cyclophosphamide 35 mg/kg on day –2). On day 0, the HSCs
were thawed in a 37°C water bath in the stem cell processing
lab at the University of Nebraska Medical Center. The cells
were slowly diluted 2 times in SyStemix sterile formulation
medium and transferred to a 30-mL syringe. A cell count
with a trypan blue viability test was performed using a hemo-
cytometer on a 100-µL sample of the thawed product. As a
result of previous human engraftment experience, a postthaw
CD34+Thy-1+ HSC viability <80% required immediate infu-
sion of the backup unselected graft as an alternative.
Following HSC infusion, G-CSF was begun on day 0 at a
dosage of 5 µg/kg per day and continued until the ANC
exceeded 2000/µL for 4 consecutive days. Packed irradiated
red blood cells were transfused when a patient’s hemoglobin
measured <8.0 g/dL, and irradiated platelets were transfused
when a patient’s platelet count was <20,000/µL, or as clini-
cally indicated. Antibiotics, including antibacterial, antifungal,
and antiviral agents, were administered according to institu-
tional policy. Patient follow-up included daily blood counts
until recovery and then as clinically indicated and/or twice
weekly until day 60 posttransplantation. Peripheral blood
absolute numbers of CD3, CD4, CD8, and CD56 cells as well
as immunoglobulin levels were evaluated at baseline, on days
28, 60, and 100, and at 1-year posttransplantation.
Statistical Analysis/Engraftment Evaluation
Neutrophil engraftment was defined as the first of
3 consecutive days that the patient achieved an ANC
>500/µL. Platelet engraftment was defined as the first of
7 consecutive days of an unsupported platelet count
>20,000/µL. Red blood cell transfusion independence was
reported as the ﬁrst of 30 consecutive days that the hemo-
globin measured >8.0 g/dL. Complete response (CR) was
deﬁned as the disappearance of all clinical and radiographic
evidence of disease (<1.5 cm) at the day +100 evaluation. A
CR undetermined (CRu) was deﬁned as some residual com-
puted tomographic abnormalities at the day +100 evaluation
that were not conclusively active disease. A partial response
(PR) was deﬁned as a ≥50% reduction in the bidimensional
measurements at the end of therapy. Overall survival was
deﬁned as the time from transplantation to death from any
cause. Event-free survival was defined as the time from
transplantation to disease progression or death from any
cause. Survival times and event-free survival distributions
were calculated using the Kaplan-Meier method [22]. Com-
parisons of these time-to-event distributions were made
using the log-rank test [23].
RESULTS
Patient Characteristics
Twenty-six patients were enrolled in this study, with
20 going on to receive high-dose BEAC and SyStemix-
selected HSC transplants. Patient characteristics by cohort
are shown in Table 1. The median age of all patients was
51 years (range, 35-63 years), with 60% of the patients being
male. Patients were receiving transplants for recurrent follic-
ular lymphoma (n = 12), recurrent small lymphocytic lym-
phoma (n = 1), recurrent marginal zone lymphoma (n = 1), or
MCL (n = 6). Eleven (55%) of the 20 patients were undergo-
ing transplantation as primary induction failures with
chemosensitive disease. Seven of the patients were undergo-
ing transplantation in first relapse with chemosensitive or
minimal disease. The other patients were in complete remis-
sion at the time of transplantation. The majority of patients
had received fewer than 3 prior chemotherapy regimens.
The other patient characteristics are noted in Table 1.
Mobilization and HSC Collection
Once they were determined to be transplantation candi-
dates, patients were mobilized with G-CSF at 24 µg/kg per
day; on the fourth day, patients were initiated on stem cell
collections as described. Four patients required 2 collections,
11 required 3 collections, and 5 required 4 collections to
obtain the minimum CD34+Thy-1+ cell count to proceed
with transplantation. Following the minimum collection of
CD34+Thy-1+ cells, the patients underwent a backup unmod-
iﬁed collection of ≥1.5 × 106 CD34+ cells/kg. Six patients did
not achieve the minimum CD34+Thy-1+ cell dose and under-
went a second mobilization attempt with cyclophosphamide
at 4 g/m2 followed by G-CSF, with collection of cells as the
patients recovered the neutrophil count. None of these
Table 1. Patient Characteristics*
Cohort 1 Cohort 2 All
Characteristic (n = 10) (n = 10) (N = 20)
Age, y, median (range) 52 (36-63) 50 (35-63) 51 (35-63)
Sex % male 60% 60% 60%
Diagnosis
Follicular 7 (70%) 5 (50%) 12 (60%)
Marginal zone 1 (10%) 0 1 (5%)
Mantle cell 2 (20%) 4 (40%) 6 (30%)
Small lymphocytic 0 1 (10%) 1 (5%)
Number of prior regimens
1-2 7 (70%) 9 (90%) 16 (80%)
3+ 3 (30%) 1 (10%) 4 (20%)
Disease status at treatment
PIF, chemosensitive 4 (40%) 7 (70%) 11 (55%)
First relapse 5 (50%) 2 (20%) 7 (35%)
CR1/CR2 1 (10%) 1 (10%) 2 (10%)
Bone marrow involved 2 (20%) 7 (70%) 9 (45%)
Elevated LDH 6 (60%) 3 (30%) 9 (45%)
*PIF indicates primary induction failure; CR, complete remission;
LDH, lactic dehydrogenase.
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6 patients with mobilization failures were able to obtain an
adequate CD34+Thy-1+ cell count with the second attempt at
chemo/cytokine mobilization. However, all 6 of these patients
did go on to transplantation with unselected stem cell prod-
ucts and demonstrated normal engraftment.
Once obtained, mononuclear cells collected by apheresis
were diluted to a ﬁnal concentration of <5 × 107 cells/mL in
proprietary transport medium before shipment to SyStemix.
At SyStemix, each patient’s sample was analyzed for cell
number, viability, and phenotype and was processed imme-
diately using the Isolex immunomagnetic positive selection
device to enrich for CD34+ cells with subsequent high-speed
flow-cytometric cell sorting for the final purification of
CD34+Thy-1+ HSCs. The median number of viable HSCs
cryopreserved was 5.3 × 105 CD34+Thy-1+ cells/kg in
cohort 1 and 4.9 × 105 CD34+Thy-1+ cells/kg in cohort 2.
The purity of the CD34+Thy-1+ cells after sorting exceeded
90% in all cases, with a median purity of 93%. The cells
were shipped back to the clinical site for infusion after the
BEAC regimen, as discussed.
Hematopoietic Stem Cell Reconstitution
Neutrophil recovery was rapid in most patients, with a
median time to reach an ANC >500/µL of 12 days (range,
9-14 days). The median time to reach an ANC >2000/µL
was 14.5 days (range, 12-20 days). The median time to red
blood cell transfusion independence was 15 days (range,
12-30 days). The median time to platelet transfusion inde-
pendence was 14.5 days (range, 11-65 days). Engraftment
times by cohort are listed in Table 2. In the range of cell
doses infused, there was no clear effect of the cell dose on
engraftment in the patients (Figure 2). The patients
received a median of 6 units of red blood cells during trans-
plantation (range, 2-29 units) and a median of 10 transfu-
sions of single-donor platelets (range, 4-44 transfusions).
No patients required their backup unmodified hemato-
poietic stem cells to be infused because of poor engraftment.
Adequate nonselected cells ≥1.5 × 106 CD34+ cells/kg
were collected from the 6 patients from whom adequate
CD34+Thy-1+Lin– cells could not be collected despite
2 mobilizations. These patients received a standard trans-
plant with these cells, and their engraftment was as follows:
Time to ANC >500/µL, 12 days; platelet independence
>20,000/µL, 14 days; and red blood cell transfusion indepen-
dence, 15 days. These engraftment times are not signiﬁcantly
different from the engraftment times of the patients receiv-
ing the SyStemix-selected products or of patients treated
previously with unselected stem cells at our institution [24].
Immune Reconstitution and Infections
Immunoglobulin levels and T-cell reconstitution by
cohort are shown in Table 3. CD4+ reconstitution was vari-
able, with patients at day +100 posttransplantation having a
median of 120 and 106 CD4+ cells/µL in cohorts 1 and 2,
respectively. These results are slightly lower than the levels
in NHL patients who received transplants at our center with
unselected stem cell products [25]. Levels of IgM, IgG, and
IgA were also depressed in several patients in the posttrans-
plantation period. Significant clinical infections in the
immediate posttransplantation period included 2 gram-
negative rod sepsis syndromes, 1 episode of influenza and
respiratory syncytial virus (RSV) requiring prolonged
Table 2. Engraftment, by Cohort*
Engraftment Cohort 1 Cohort 2 All
Days to ANC >500/µL, 12 (10-13) 12 (9-14) 12 (9-14) 
median (range)
Days to ANC >2000/µL, 15 (13-19) 14.5 (12-20) 14.5 (12-20)
median (range)
Days to RBC independence, 20 (15-25) 11.5 (12-30) 15 (12-30)
median (range)
Days to platelet independence, 19 (11-65) 12 (11-20) 14.5 (11-65)
median (range)
*RBC indicates red blood cell.
Figure 2. Engraftment as a function of HSC dose.
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intubation in a patient, and 1 episode of RSV requiring brief
intubation. Later (>100 days posttransplantation), there
were 5 cases of varicella zoster, 1 episode of Pneumocystis
pneumonia, 1 episode of systemic candidiasis, and 2 episodes
of interstitial pneumonitis without a speciﬁc pathogen being
identiﬁed, requiring intubation.
Toxicity
The acute and chronic infectious complications are as
outlined above. Additional toxicities seen in the transplant
recipients included temporary renal insufﬁciency requiring
dialysis in 1 patient, seizures associated with the influenza
and RSV infections in 1 patient, and congestive heart fail-
ure, which was treated medically, in 1 patient. There were
no toxic deaths in the patients within the ﬁrst 100 days post-
transplantation. Nine of the 20 patients have failed, most as
a result of progressive disease (n = 8). Five patients have
died, 4 of progressive disease and 1 of pulmonary ﬁbrosis at
17 months posttransplantation.
Minimal Residual Disease Studies
Six patients were found to have minimal residual disease
in their apheresis product prior to processing. Four patients
with follicular lymphoma had a positive ﬁnding for the bcl-2
rearrangement, and 2 patients with MCL had a positive
ﬁnding for the bcl-1 rearrangement by PCR. The patients
had a >3.26- to >5.68-fold reduction (log 10) with the
CD34+Thy-1+ cell sorting process (Table 4). 
Patient Outcomes
At a median follow-up of 38 months (range, 35-49 months),
8 patients had progressed and 1 patient had died of pul-
monary fibrosis at 17 months posttransplantation. This
patient had a preexisting scleroderma-type syndrome that
appeared to accelerate after transplantation, with manifesta-
tions of pulmonary ﬁbrosis. The responses in the patients in
the trial are CR/CRu in 14 (70%) and PR in 5 (25%). Over-
all survival in all patients is 78% at 36 months posttrans-
plantation (Figure 3). Event-free survival in all patients is
55% at 36 months, with no difference seen by dose cohort
(Figure 4). Additionally, no difference in event-free survival
was seen by presence or absence of minimal residual disease
in the transplantation product. Sites of relapse included
nodal areas (n = 6), pulmonary parenchyma (n = 1), and
1 unknown site. All nodal areas were sites of previous dis-
ease; the pulmonary parenchyma was a new site of disease.
DISCUSSION
The use of high-dose chemotherapy and autologous
transplantation for patients with recurrent indolent NHL is
somewhat controversial because no survival advantage over
standard therapy has been documented [3-5]. In addition, the
use of high-dose chemotherapy and autologous transplanta-
tion has not led to long-term disease-free survival in most
patients with relapsed MCL [7]. Concerns of lymphoma
contamination of the stem cell product and the possible rein-
fusion of these cells and its contribution to relapse have led
to many clinical trials involving purging of cell products
[4,6]. In addition, positive selection of CD34+ cells has now
been evaluated in several clinical trials evaluating a cell avidin
CD34+ selection device that releases CD34+ cells by mechan-
ical agitation [14]. Positive selection using an immunomag-
netic bead device has also been evaluated in clinical trials
[13]. Both devices have been reported to allow adequate and
sustained engraftment with a decrease in the tumor cell con-
tamination of the graft. The CD34+ selection device has
been compared to unselected transplantation in patients with
multiple myeloma and found to have equivalent clinical out-
comes [26]. In the current clinical trial evaluating
CD34+Thy-1+Lin– cells, a highly selected stem cell product
is produced as an avenue toward further decreasing tumor
contamination while still allowing rapid engraftment of the
hematopoietic and immune systems posttransplantation.
This study demonstrated the feasibility and safety of har-
vesting unmodified hematopoietic progenitors with long-
distance shipment to a high-speed cell sorting facility
(SyStemix) and subsequent successful transplantation and
engraftment with these cells in patients receiving high-dose
chemotherapy and HSC transplants for follicular NHL or
MCL. Previous phase 2 studies have also been reported in
patients undergoing transplantation for breast cancer and
multiple myeloma [19,26,27]. In the current trial, 20 of
26 patients with relapsed or high-risk ﬁrst complete remission
NHL were able to have adequate numbers of hematopoietic
stem cells harvested using G-CSF alone to have a minimum
number of CD34+Thy-1+ cells collected. In the 6 patients
Table 3. Immunoglobulin and T-Cell Reconstitution After Transplantation
(Median Values)
Day 28 Day 60 Day 100 Day 365
Cohort 1 (normal values)
CD3/µL (603-2849) 122 588 419 795
CD4/µL (312-2064) 33 241 120 159
CD56/µL (18-578) 161 97 89 78
CD8/µL (113-1272) 214 1058 318 648
IgM, mg (40-214) 32 32 66 68
IgG, mg (680-1530) 823 677 882 873
IgA, mg (75-374) 99 68 117 93
Cohort 2
CD3/µL 141 581 448 630
CD4/µL 48 147 106 213
CD56/µL 79 156 73 86
CD8/µL 97 440 301 413
IgM, mg 36 34 57 99
IgG, mg 707 629 785 941
IgA, mg 109 105 127 152
Table 4. Minimal Residual Disease Reduction, by CD34+Thy-1+ Cell Sorting*
Apheresis, No. of
Patient No. PCR Tumor Cells CD34+† CD34+Thy-1+†
105 bcl-1 7.44 × 106 NA >4.32
111 bcl-2 8.19 × 105 >2.78 >3.26
119 bcl-2 1.05 × 107 3.6 >4.14
121 bcl-1 1.17 × 108 NA >5.65
125 bcl-2 1.21 × 107 3.95 >5.68
126 bcl-2 4.51 × 107 5.07 >5.61
*NA indicates not available.
†Absolute fold reduction (log 10).
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from whom adequate cells could not be collected by mobi-
lization with cytokine alone, adequate cells also could not be
collected with cyclophosphamide plus cytokine mobilization.
Murine models had previously demonstrated that highly
enriched populations of HSCs are capable of engrafting
lethally irradiated animals with cells that behave similarly to
bone marrow–derived cells [28]. The 3 previous studies in
humans in patients with breast cancer and multiple
myeloma demonstrated excellent neutrophil engraftment in
most patients, with some concern about delayed platelet
engraftment in 1 of the trials in patients with multiple
myeloma [19]. In the study by Tricot et al. [19], 10 patients
with multiple myeloma underwent stem cell collection with
cyclophosphamide and granulocyte-macrophage CSF.
These cells then were sent for the high-speed cell sorting of
CD34+Thy-1+ cells. Nine of the 10 patients met the mini-
mum criteria of 7.2 × 105 cells/kg and received transplants
using high-dose melphalan. Eight of the 9 had successful
engraftments; however, the median times to an ANC
>500/µL of 16 days and a platelet count >50,000/µL of
39 days were substantially delayed compared with the
median times achieved by historical control patients receiv-
ing unmanipulated HSC grafts [19]. One patient required
infusion of the reserve unmanipulated HSCs because of lack
of engraftment at day +28.
A more recent publication, by Michallet et al. [29], eval-
uated 23 patients with multiple myeloma who received mel-
phalan and total body irradiation with CD34+Thy-1+-
selected cells as the graft source. In this study, patients who
received >0.8 × 106 CD34+Thy-1+ HSC/kg had prompt
engraftment, with a median time to an ANC >500/µL of
10 days and a median time to a platelet count >50,000/µL of
13 days. Additionally, prompt engraftment was reported by
Negrin et al. [27] in 22 patients with breast cancer undergo-
ing high-dose chemotherapy with carmustine, cisplatin, and
cyclophosphamide and CD34+Thy-1+-selected cells. The
median time to reach an ANC >500/µL was 10 days, and the
median time to reach a platelet count >50,000/µL was
17 days. Engraftment in our study was prompt for neu-
trophils >500/µL at a median of 12 days and satisfactory as
well for platelet transfusion independence at a median of
14.5 days.
A concern with the highly selected stem cell products
has been delayed immune reconstitution and the possibility
of infectious complications as a result. In the 2 myeloma
studies, the authors felt that compared with similar patients
receiving unselected HSC transplants, the patients in the
SyStemix trials experienced more short- and long-term
infectious complications. In the study by Michallet et al.,
pulmonary aspergillosis and cytomegalovirus and varicella
zoster infections were seen in a high percentage of patients
who received <0.8 × 106 HSC/kg [29]. The study with
breast cancer patients demonstrated a delayed time to
engraftment of CD4+ and CD8+ cells but no major infec-
tious complications [27]. Our current study of the SyStemix-
isolated cells for reconstitution for patients with NHL also
demonstrates some delays in CD4+ and CD8+ engraftment
and some unanticipated viral infections. This increase in
viral infections has also been reported in patients undergo-
ing CD34+ selection by other techniques [30].
An additional object of this trial was to evaluate the pos-
sible effects of decreasing the minimal residual disease in the
hematopoietic stem cell product infused in the hope that
such a decrease would reduce the potential relapse rate in
patients. Out of 20 patients who received transplants, 6 had
an identified minimal residual disease marker in their
apheresis product. An overall >3 to 5 log reduction of tumor
cells was identiﬁed with the CD34+Thy-1+ selection process
in these patients. However, in this small group of patients,
this reduction did not appear to inﬂuence the outcome. In
the breast cancer trial, all apheresis products were able to
have successful log depletions of tumor cells [27]. The mul-
tiple myeloma studies also demonstrated successful tumor
depletion [19,29]. 
This study has demonstrated the feasibility of isolation
of CD34+Thy-1+ stem cells by high-speed cell sorting after
long-distance shipment of the product. In addition, tumor
depletion of the product was demonstrated. Rapid neu-
trophil and platelet engraftment were seen in the majority of
patients, with no requirement for the backup stem cell prod-
uct to be infused. However, delayed immunologic reconsti-
tution and a slightly higher than expected incidence of cer-
tain types of opportunistic infections remain a concern. It is
unknown whether this approach will make a difference in
the long-term outcomes of patients receiving high-dose
chemotherapy and stem cell transplantation for lymphoma.
Figure 3. Overall survival of patients receiving transplants.
Figure 4. Event-free survival of patients receiving transplants, by
dose cohort.
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